Add BrightSurf on Google Email

Weill Cornell Medicine


Long-term immune response to SARS-CoV-2 mRNA vaccination is unaffected by pregnancy

A recent study published in the American Journal of Obstetrics & Gynecology MFM found that pregnant individuals have a similar long-term immune response to SARS-CoV-2 mRNA vaccination as non-pregnant individuals. The study also showed that vaccination during pregnancy provides protection to unborn babies, which is essential for their C...

SourceWeill Cornell Medicine·JournalAmerican Journal of Obstetrics & Gynecology MFM·DateDec 13, 2022

Faulty DNA repair may lead to BRCA-linked cancers

A new study by Weill Cornell Medicine investigators discovered that error-prone DNA replication and repair may lead to mutations and cancer in individuals with BRCA1 gene mutations. The team identified a faulty DNA repair mechanism called microhomology-mediated break-induced replication (MMBIR) as a key contributor to genomic instabili...

SourceWeill Cornell Medicine·JournalMolecular Cell·DateNov 15, 2022

Mantle cell lymphoma treatment varies according to setting

The study found that autologous stem cell transplantation (ASCT) was underutilized in community settings, but maintenance therapy after standard therapy improved outcomes for patients over 65. Maintenance rituximab after bendamustine and chemotherapy regimens also significantly extended times to disease progression and overall survival.

SourceWeill Cornell Medicine·JournalJournal of Clinical Oncology·DateJun 28, 2022

New cancer subtype may illuminate treatment strategy

Researchers have identified a previously unrecognized form of hormone therapy-resistant prostate cancer and found promising drug targets to treat it. The discovery opens the door to developing therapies that specifically target this disease, which accounts for approximately a quarter of castration-resistant prostate cancers.

SourceWeill Cornell Medicine·JournalScience·DateMay 27, 2022

Benefits of PSA prostate cancer screening found to be more favorable than previous estimates, especially for blacks

New research suggests that PSA screening has remarkably favorable tradeoffs, particularly for Black men, who disproportionately bear the burden of prostate cancer mortality and morbidity. The study's findings support the use of PSA screening for high-risk groups, including Black men, and highlight the need to revise clinical guidelines...

SourceWeill Cornell Medicine·JournalNEJM Evidence·DateMay 15, 2022